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ABSTRACT This study characterized the in vitro potencies of antileishmanial agents
against intracellular Leishmania donovani amastigotes in primary human macro-
phages, obtained with or without CD14-positive monocyte enrichment, phorbol 12-
myristate 13-acetate (PMA)-differentiated THP-1 cells, and mouse peritoneal exudate
macrophages (PEMs). Host cell-dependent potency was conﬁrmed for pentavalent
and trivalent antimony. Fexinidazole was inactive against intracellular amastigotes
across the host cell panel. Fexinidazole sulfone, (R)-PA-824, (S)-PA-824, and VL-2098
displayed similar potency in all of the host cells tested.
KEYWORDS drug potency, host cell, Leishmania donovani
Parasites of the genus Leishmania are causative agents of neglected tropical diseases(NTDs) known as the leishmaniases. In the host, parasites survive and multiply as
intracellular amastigotes in the parasitophorous vacuole of primarily tissue-resident
macrophages (1). Main disease manifestations include visceral leishmaniasis (VL) (2) and
cutaneous leishmaniasis (CL) (3). VL is caused by infection with Leishmania donovani or
Leishmania infantum (2) and is estimated to cause more than 50,000 deaths per year (4).
Limitations of current chemotherapeutics include the need for long treatment courses,
variable treatment responses between regions where VL is endemic, safety concerns,
and lack of drug stability in hot climates (5, 6). With increased support for drug research
and development for NTDs, the last decade has seen increased efforts in drug discovery
for leishmaniasis. This was accompanied by the setup of high-throughput, high-content
platforms to screen compounds against intracellular Leishmania amastigotes in mam-
malian host cells (7–9). Different mammalian cells are used for this purpose. However,
host cell properties are among the determinants of directly acting drugs, which need
to accumulate in infected host cells to exert their antileishmanial effects, and immu-
nomodulatory agents, which affect cellular pathways to kill intracellular parasites
indirectly. The involvement of host cell transporters has been demonstrated in drug
accumulation and treatment outcome for antimonials (10, 11) and miltefosine (12). The
nature of the host cell has been shown to impact on the in vitro potency of the standard
antileishmanial drug sodium stibogluconate (SSG) (13). Hence, the current study was
undertaken to characterize the potencies of current lead compounds and drug candi-
dates against intracellular L. donovani amastigotes in a panel of different host cells.
The selection of host cells was focused on human-derived cells to ensure relevance
to clinical use. Peritoneal exudate mouse macrophages (PEMs) were included, as they
have an established role in antileishmanial drug evaluations. Compounds proﬁled
included the nitroheterocyclic drugs fexinidazole and its sulfone metabolite (14),
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VL-2098 (15), and the (R) and (S) enantiomers of PA-824 (16). Notably fexinidazole has
entered clinical trials for VL (www.dndi.org). Since SSG (pentavalent antimony) is a
prodrug and requires conversion to the trivalent form (17), we included both oxidation
states in the current study.
THP-1 cells (ATCC TIB-202; LGC Ltd., Teddington, UK), PEMs harvested from BALB/c
or CD-1 mice (London School of Hygiene and Tropical Medicine [LSHTM] breeding
colony), and human peripheral blood mononuclear cells (PBMCs) harvested from
heparinized blood collected from adult human donors were prepared as described
previously (13). Autologous plasma was centrifuged for 30 min at 2,000 g at 20°C and
stored at 4°C for the duration of the experiment. Mononuclear cells were resuspended
in RPMI 1640 medium plus penicillin (100 U/ml), streptomycin (100 g/ml), and 10%
autologous plasma and differentiated at 37°C and 5% CO2 for a total of 6 days with the
addition of fresh medium after 3 days. Selected assays used monocytes obtained
through positive immunomagnetic selection with CD14 MicroBeads (MACS; Miltenyi
Biotec) following the manufacturer’s recommendations. The CD14-positive monocyte-
enriched fraction was resuspended in RPMI 1640 medium plus 10% heat-inactivated
fetal bovine serum (hi-FBS), 100 ng/ml recombinant human macrophage colony-
stimulating factor (M-CSF) (R&D Systems, UK), and penicillin (100 U/ml)-streptomycin
(100 g/ml) and differentiated at 37°C and 5% CO2 for 6 days. Prior to infection, cells
were washed with fresh medium containing no antibiotic. Depending on the ﬁnal
number of cells obtained, PBMC-derived macrophages from 2 to 3 individual donors
were either combined or plated separately for drug potency evaluations. At the time of
drug addition, cells obtained without CD14 selection were 85% macrophages as
estimated by morphological appearance in Giemsa-stained preparations and those
obtained with positive CD14 selection were 100%. Host cells, plated in Lab-Tek 16-well
chamber slides (Fisher Scientiﬁc, UK) at a density of 4  104 cells/well, were infected
with Leishmania donovani (MHOM/ET/67/HU3) amastigotes harvested from Rag-1-
knockout (B6) mice (LSHTM breeding colony) as described previously (13). Infected
cultures were exposed to 6 point (4 point when limited by cell number) serial com-
pound dilutions (2-fold and 3-fold for antimonials) or assay medium (untreated con-
trols) for 3 days (no medium change) or 5 days (medium change after 3 days). Each
concentration and control was tested in quadruplicate. Upon termination of the assay,
slides were prepared and data were evaluated as described previously (13). The
percentage of infected cells was used to estimate 50% effective concentration (EC50)
and 90% effective concentration (EC90) values as the clinically most relevant read out.
Intracellular burden in untreated controls was determined by counting the number of
amastigotes in 50 infected host cells per well. Experiments were carried out in a direct
comparative assay design in which different host cell types were infected at the same
time with the same batch of parasites and exposed to dilutions prepared from the same
stock solution of compounds. This approach was chosen to ensure that any variation in
drug potency between different cell types could be attributed to cell type rather than
to day-to-day differences in parasite or drug preparation. Structurally related com-
pounds were tested in parallel in the same experiment, and miltefosine (Zentaris
GmbH, Germany) was included as a standard drug in selected assays. Nitroheterocyclic
drugs were synthesized at the University of Dundee as described previously (14, 16).
VL-2098 was prepared in a single step from 4-(Triﬂuoromethoxy)phenol and (R)-2-
bromo-1-((2-methyloxiran-2-yl)methyl)-4-nitro-1H-imidazole using a modiﬁcation of the
published synthesis of delamanid (OPC-67683) (18). Potassium antimonyl tartrate tri-
hydrate (trivalent antimony) was obtained from Sigma (UK), and SSG was obtained from
GSK (UK). Aqueous stock solutions of SSG, potassium antimonyl tartrate trihydrate, and
miltefosine were prepared as described previously (13), and those of other compounds
were prepared in dimethyl sulfoxide (Sigma, UK).
Experiments involving animals were approved by the Animal Welfare and Ethics
Review Board at LSHTM and performed under license in accordance with the Animals
(Scientiﬁc Procedures) Act 1986 (UK Home Ofﬁce project license PPL70/6997). For blood
donations, consenting volunteers were recruited through an anonymous blood dona-
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tion system. Approval for blood donations and the speciﬁc study was given by the
LSHTM Ethics Committee (reference numbers 5520 and 6404).
At the EC50 level, both pentavalent and trivalent antimony were more potent
against L. donovani amastigotes in primary human macrophages than in differentiated
THP-1 cells by factors of 21 to 100. The difference in the potency of SSG between
these two cell types is consistent with previous observations (13). As different meth-
odologies exist for the generation of primary human macrophages (10, 13, 19) and cells
obtained from total PBMC fractions by plastic adherence may contain lymphocyte and
platelet contaminations (20), we wanted to rule out that the methodology used
affected our conclusion. Hence, we additionally evaluated the potency of SSG in
macrophages generated from CD14-positive enriched monocytes. Again, SSG was more
potent in primary human macrophages than in differentiated THP-1 cells tested in
parallel, with up to 20-fold differences at the EC50 level. Also, SSG already displayed
antileishmanial activity in primary human macrophages after 3 days of exposure when
either isolation method was used. Data are summarized in Table 1. In macrophages
obtained from CD14-positive enriched monocytes, EC90 values were consistently higher
than those estimated in macrophages obtained from total PBMC fractions. However, a
systematic comparison of the potencies of SSG between the two cell isolation proce-
dures was outside the scope of this study. Since the in vitro potency of SSG has been
shown to decrease with increasing infection levels (21), it is important to note that
infection levels in macrophages obtained from CD14-positive enriched monocytes or
differentiated THP-1 cells were not higher than those in macrophages obtained from
total PBMC fractions (data not shown).
Antileishmanial potencies of the nitroheterocyclic compounds (R)-PA-824, (S)-PA-
824, and VL-2098 displayed less than 3-fold differences against amastigotes in primary
human macrophages compared to those in differentiated THP-1 cells at the EC50 and
EC90 levels after 3 days of compound exposure. Previously reported differences in
antileishmanial activity between the two enantiomers of PA-824 (16) were conﬁrmed in
both human-derived host cells. Larger variations between assays were observed for
fexinidazole sulfone, resulting in 2- to 10-fold differences at the EC50 level. However,
variable quality of dose response curve ﬁts, as checked visually, was noted between
experiments. Fexinidazole was inactive at concentrations of up to 80 M in both
TABLE 1 Characterization of cell type-dependent potency of antimonials in primary human macrophages and differentiated THP-1 cells
Antimonial Expta Daysb
PBMC-derived mc Differentiated THP-1 cells PBMC-derived m (CD14)d
EC50 (g Sb/ml
[95% conﬁdence
interval])
EC90 (g Sb/ml
[95% conﬁdence
interval])
EC50 (g Sb/ml
[95% conﬁdence
interval])
EC90 (g Sb/ml
[95% conﬁdence
interval])
EC50 (g Sb/ml
[95% conﬁdence
interval])
EC90 (g Sb/ml
[95% conﬁdence
interval])
SbV 1 3 5.39 (4.68–6.11) 10.22 (9.59–10.86) NDe ND ND ND
SbV 2 5 5.17 (4.62–5.71)f 11.20 (9.48–12.92)f 108.76 (53.52–164.00) 200 ND ND
2 5 2.43 (1.66–3.20)f 10.27 (4.14–16.39)f
SbIII 2 5 0.10 (0.09–0.11)f 0.17f 10 10 ND ND
2 5 0.08 (0.07–0.08)f 0.17f
SbV 3 3 ND ND 900 900 15.08 (11.70–18.46)g 30g,h
3 5 ND ND 117.62 (84.91–150.34) 900 11.11 (8.58–13.65)f,g 30f,g,i
3 5 ND ND 6.01 (5.59–6.42)f 30f,j
aExperiment numbers indicate parallel testing of antimonials in assays with the same number. Miltefosine was included as a positive control and displayed EC50/EC90
values (95% conﬁdence intervals in parentheses) of 7.97 M (4.47 to 11.47)/20 M in differentiated THP-1 cells and 1.61 M (1.24 to 1.98)/5 M in PBMC-derived
macrophage (m) in experiment 1. In experiment 2, respective values were 1.64 M (1.35–1.93)/7.77 M (6.42–9.12) and 1.42 M (1.38–1.45)/3.92 M (2.78–5.07).
bDays indicate the number of days of continuous drug exposure.
cPBMC-derived m refers to macrophages obtained without positive (CD14) selection.
dPBMC-derived m (CD14 positive [CD14]) refers to macrophages obtained from positively selected (CD14) monocytes.
eND, not determined.
fCells were derived from two individual blood donors.
gCells were derived from the same blood donor.
hPercentage inhibition at 30 g Sb/ml was 51.6%.
iPercentage inhibition at 30 g Sb/ml was 73.3%.
jPercentage inhibition at 30 g Sb/ml was 77.8%.
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human-derived cell types. Data are summarized in Table 2. Due to the absence of
apparent host cell-dependent drug action, no further investigation was carried out for
nitroheterocyclic compounds in macrophages generated from CD14-positive enriched
monocytes. Estimation of the steepness of the dose response curves through Hill slopes
gave values of 1 for VL-2098, (R)-PA-824, and (S)-PA-824 and 1 for fexinidazole
sulfone. Levels of infection in human-derived host cells were similar and increased over
the course of the experiments but differed in PEMs (data not shown). Hence, potencies
against L. donovani amastigotes in PEMs are reported in Table 2 without direct
comparisons to the human-derived cells. Potencies were in agreement with values
reported in the literature (14–16).
Cell lines are often used over primary cells due to ease of culture and an argument
of homogeneity. Phorbol 12-myristate 13-acetate (PMA)-differentiated THP-1 cells are
widely used in antileishmanial drug research, but different stimulation conditions are
reported (7, 8, 10, 22). The host cell’s ability to sustain infection with Leishmania
parasites and comparison of the potencies of reference compounds to other host cells
and assay formats have been the focus in developing protocols for antileishmanial drug
evaluation using differentiated THP-1 cells. However, it has been shown that certain cell
characteristics, including lysosomal structures, differ when different stimulus conditions
are used (23). Lowering extracellular oxygen tension from 18% to 5% O2 has also been
shown to affect PMA-induced THP-1 cell differentiation and function (24). So far, these
effects have not been explored in antileishmanial drug research.
Using primary human macrophages derived from individual blood donors, we found
drug potencies to be consistent between different donors (Fig. 1); however, monocyte
isolation requires a more dedicated approach than standard cell culture, and macro-
phage yields are less predictable.
In summary, we show that antimonials are a class of compounds where the choice
of host cell affects drug potency under the conditions tested and provide potency
proﬁles of current antileishmanial lead and drug candidates in human-derived host
cells, including primary macrophages. Antimonials have been shown to cause oxidative
stress and activation of L. donovani-infected host cells in vitro with the generation of
reactive oxygen species (ROS), nitric oxide (NO), and tumor necrosis factor alpha
TABLE 2 Potency of nitroheterocyclic compounds against intracellular L. donovani amastigotes in three different host cell typesa
Drug Exptb
Differentiated THP-1 cells PBMC-derived m PEMs
EC50 (M [95%
conﬁdence interval])
EC90 (M [95%
conﬁdence interval])
EC50 (M [95%
conﬁdence interval])
EC90 (M [95%
conﬁdence interval])
EC50 (M [95%
conﬁdence interval])
EC90 (M [95%
conﬁdence interval])
(R)-PA-824 1 2.91 (2.77–3.04) 6.56 (4.66–8.47) 4.59 (4.15–5.03)c 5.76 (5.25–6.27)c 1.16 (0.89–1.42) 5.58 (3.25–7.92)
1 2.63 (2.37–2.89)c 4.92 (4.36–5.47)c
2 4.01 (3.94–4.09) 8.39 (6.93–9.58) 5.06 (4.55–5.57) 7.27 (6.46–8.09) 2.26 (2.09–2.44)d 4.55 (3.46–5.64)d
(S)-PA-824 1 27.83 (24.95–30.71) 40 38.62 (37.53–39.70) 40 13.03 (8.05–18.02) NOe
2 27.90 (25.32–30.49) 50.82 (44.66–26.97) 30.57 (26.73–34.41) 37.82 (35.88–39.77) 13.53 (11.67–15.39)d NOd
VL-2098 1 0.22 (0.21–0.23) 0.36 (0.32–0.41) 0.32 (0.31–0.34) 0.48 (0.45–0.50) 0.23 (0.20–0.26) 0.45 (0.37–0.54)
2 NDf ND 0.39 (0.36–0.42) 0.56 (0.52–0.61) 0.23 (0.21–0.24)d 0.45 (0.35–0.56)d
3 ND ND 0.27 (0.21–0.33) 0.41 (0.39–0.43) ND ND
Fexinidazole 3 80 80 80c 80c 80 80
3 80c 80c
Fexinidazole
sulfone
1 3.15 (2.06–4.25) 20 7.57 (6.72–8.43)c 40c 5.59 (5.21–5.96) 20
1 6.85 (4.56–9.13)c 40c
3 8.43 (7.38–9.49) 40 9.37 (4.66–14.07)c 80c 10.44 (6.88–14.00) 40
3 14.70 (10.73–18.68)c 80c
4 2.24 (1.42–3.06) 80 20.94 (17.02–24.86) 80 10.27 (5.64–14.90) 20
aData is representative of 2 to 4 separate directly comparative experiments.
bExperiment numbers indicate parallel testing of respective compounds in assays with the same number. Miltefosine was included as a positive control in experiment
4 and displayed EC50 values (95% conﬁdence intervals in parentheses) of 8.58 M (6.39 to 10.76) in differentiated THP-1 cells, 2.67 M (1.78 to 3.57) in PBMC-derived
m, and 1.19 M (0.83 to 1.54) in PEMs.
cCells were derived from two individual blood donors.
dPEMs were harvested from CD-1 mice in this assay and BALB/c mice in all other assays.
eNO, not obtained.
fND not determined.
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(TNF-) and subsequent killing of intracellular parasites (25, 26). Drug transporters at
the host cell level have been linked to clinical responses to antimonial treatment and
drug resistance (10, 11, 27). Modulation of gene expression proﬁles by SSG has also
been demonstrated in vitro, and increased levels of glutathione were measured in
SSG-treated cells compared to untreated host cells (28). It is possible that differences in
the response to oxidative stress, production of cytokines, expression of drug transport-
FIG 1 Comparison of EC50s between primary human macrophages obtained from different blood donors. Data are
given for 3-day exposures to fexinidazole sulfone (A), (R)-PA-824 (B), (S)-PA-824 (C), VL-2098 (D), and for 5-day
exposures to SSG (E). Symbols represent results with cells from individual blood donors (ﬁlled circles) or with cells
pooled from 2 to 3 individual blood donors (ﬁlled triangles).
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ers, or a combination of these factors between different host cells account for the host
cell-dependent phenotype of antimonial drug action.
To enable evidence-based host cell choice in antileishmanial drug research, system-
atic functional characterization of the different cell types and their cell-parasite inter-
actions are needed. Finally, the lack of antileishmanial activity of fexinidazole in all three
cell types tested underlines the importance of drug metabolism for successful treat-
ment outcomes with this drug.
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